We showed that genetic knockdown of S6k1 had no beneficial effect on the levels of aggregated mHTT or on any of the behavioural or physiological deficits observed in the R6/2 mouse model, indicating that inhibition of S6K1 is unlikely to be of benefit in the treatment of HD. This evidence concerns the gene RPS6KB1 and Huntington disease.